ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

Men face sharper brain aging from obesity and heart risks

Obesity and cardiovascular risk factors accelerate brain volume loss, with males experiencing earlier and more significant impacts, highlighting the importance of early interventions to prevent

December 2, 2024

Study unravels the prognostic paradox of isolated cardiac sarcoidosis

Sarcoidosis is a complex inflammatory disease that causes the harmful accumulation of tiny clumps of cells called granulomas in the body.

October 30, 2023

Teens’ High BMI Tied to Early Chronic Kidney Disease

High body mass index (BMI) at ages 16 to 20 was associated with chronic kidney disease (CKD) in early adulthood, a large cohort study showed.

December 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.